Immune booster shows promise for bipolar depression
NCT ID NCT04133233
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether a low dose of interleukin-2 (IL-2), a protein that helps regulate the immune system, could improve depressive symptoms in people with bipolar disorder. Fourteen participants already on mood stabilizers received the treatment. The goal was to see if it increased certain immune cells and eased depression.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BIPOLAR DEPRESSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pr Marion Leboyer
Créteil, Hôpital Albert Chenevier, 94010, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a single psychedelic dose rewire the depressed brain?
- Can brain implants read and treat bipolar depression without triggering mania?
- Brain wave patterns and inflammation: a clue to ECT's effectiveness in older adults?
- Could a common antibiotic and supplement lift bipolar depression?
- Could a new pill ease bipolar depression in young people?
- Can a blood test predict who will respond to ketamine for depression?